Skip to main content
Premium Trial:

Request an Annual Quote

Venter Announces $500K Prize for Significant Advances Toward $1,000 Genome

SAVANNAH, GA Sept. 23 (GenomeWeb News) - Just before lunch today at the GSAC conference, Craig Venter stood before the crowd and announced a mouth-watering proposition: a $500,000 Genomic Technology Prize to be awarded by the J. Craig Venter Science Foundation to a person or organization that develops technology "to significantly advance" automated DNA sequencing toward making the $1,000 genome a reality.


"Look at [the number of] important medical, and environmental advances that would happen if we could sequence a genome in the same time as we are having this conversation," Venter told GenomeWeb News today after the session ended. While this holy grail of genomics is still some time away, Venter said the prize was one of the "novel ways" to shorten the time course of discovery for this new technology. "We hope it will be an exciting stimulant for scientists," he said.


Currently, it costs about $300,000 to $500,000 to sequence the gene and regulatory regions of a human genome, and about $25 million for 5X coverage of the genome, according to the foundation. "It is necessary that these cost decrease significantly toward the $1,000 mark," the foundation said in announcing the prize. "Once this threshold has been reached it will be feasible for the majority of individuals to have their genome sequenced and encoded as part of their medical record."


The foundation is setting up an international prize committee "that will be making the initial evaluation of what are to be considered the seminal advances that permit" the $1,000 genome to be possible, Venter told the GSAC audience.


The prize is to be awarded one time only. The foundation will announce the complete rules and procedures for prize applications in late December 2003, after a meeting of its Prize Committee, according to the foundation's press statement (

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.